Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis (HET-NET)

University Medical Center Groningen (UMCG)

Status: Completed

Conditions: Neuroendocrine Tumors

Treatments: Other: Metastasized intestinal NET

Study type: Observational

Funder types: Other

Identifiers

NCT02646644

201501247

Details and patient eligibility

About

In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalaninepositron emission tomography (18F-DOPA-PET) scan.

This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan retrospectively.

Full description

In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalanine positron emission tomography (18F-DOPA-PET) scan.

This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan in retrospect.

Enrollment: 38 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age ≥18 years
• diagnosis of intestinal NET diagnosed by a dedicated NET specialist
• more than one positive lesion on the 18F-DOPA-PET scan.
• available CT-scan within 6 months before or after the 18F-DOPA-PET-scan.

Exclusion criteria

• no clinical data available at the UMCG, besides the results of the DOPA PET scan.

Trial design

38 participants in 1 patient group

Metastasized intestinal NET

Description:

We will select the 18F- DOPA-PET scans conducted in the Universtiy Medical Center of Groningen (UMCG) of adult patients with a metastasized intestinal NET between February 2014 until November 2015. Only patients of whose clinical data are available within the UMCG are included.

Treatment:

Other: Metastasized intestinal NET